184 related articles for article (PubMed ID: 32623069)
21. Luigi Naldini on His Lifelong Involvement with the Development of Gene Therapy.
Wilson JM
Hum Gene Ther Clin Dev; 2016 Sep; 27(3):83-6. PubMed ID: 27556334
[No Abstract] [Full Text] [Related]
22. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Labrosse R; Chu JI; Armant MA; Everett JK; Pellin D; Kareddy N; Frelinger AL; Henderson LA; O'Connell AE; Biswas A; Coenen-van der Spek J; Miggelbrink A; Fiorini C; Adhikari H; Berry CC; Cantu VA; Fong J; Jaroslavsky J; Karadeniz DF; Li QZ; Reddy S; Roche AM; Zhu C; Whangbo JS; Dansereau C; Mackinnon B; Morris E; Koo SM; London WB; Baris S; Ozen A; Karakoc-Aydiner E; Despotovic JM; Forbes Satter LR; Saitoh A; Aizawa Y; King A; Nguyen MAT; Vu VDU; Snapper SB; Galy A; Notarangelo LD; Bushman FD; Williams DA; Pai SY
Blood; 2023 Oct; 142(15):1281-1296. PubMed ID: 37478401
[TBL] [Abstract][Full Text] [Related]
23. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
24. Broadening the indications for hematopoietic stem cell genetic therapies.
Williams DA
Cell Stem Cell; 2013 Sep; 13(3):263-4. PubMed ID: 24012366
[TBL] [Abstract][Full Text] [Related]
25. Medicine. Gene therapy that works.
Verma IM
Science; 2013 Aug; 341(6148):853-5. PubMed ID: 23970689
[No Abstract] [Full Text] [Related]
26. Gene therapy: primed for take-off.
Leboulch P
Nature; 2013 Aug; 500(7462):280-2. PubMed ID: 23955226
[No Abstract] [Full Text] [Related]
27. [Wiskott-Aldrich syndrome: a new advance in gene therapy].
Nau JY
Rev Med Suisse; 2015 Apr; 11(472):996-7. PubMed ID: 26062229
[No Abstract] [Full Text] [Related]
28. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
[TBL] [Abstract][Full Text] [Related]
29. Solving the problem of γ-retroviral vectors containing long terminal repeats.
Persons DA; Baum C
Mol Ther; 2011 Feb; 19(2):229-31. PubMed ID: 21289636
[No Abstract] [Full Text] [Related]
30. Gene therapy for Wiskott-Aldrich Syndrome.
Bosticardo M; Ferrua F; Cavazzana M; Aiuti A
Curr Gene Ther; 2014; 14(6):413-21. PubMed ID: 25245089
[TBL] [Abstract][Full Text] [Related]
31. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells.
Strom TS; Turner SJ; Andreansky S; Liu H; Doherty PC; Srivastava DK; Cunningham JM; Nienhuis AW
Blood; 2003 Nov; 102(9):3108-16. PubMed ID: 12855574
[TBL] [Abstract][Full Text] [Related]
32. Hopes, Promises, and Future Directions of Gene and Cell Therapies in France.
Cartier N; Cordelier P
Hum Gene Ther; 2016 Feb; 27(2):96-7. PubMed ID: 26886830
[No Abstract] [Full Text] [Related]
33. How I manage patients with Wiskott Aldrich syndrome.
Rivers E; Worth A; Thrasher AJ; Burns SO
Br J Haematol; 2019 May; 185(4):647-655. PubMed ID: 30864154
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for Wiskott-Aldrich syndrome: here to stay.
Candotti F
Lancet Haematol; 2019 May; 6(5):e230-e231. PubMed ID: 30981782
[No Abstract] [Full Text] [Related]
35. Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs.
Six E; Guilloux A; Denis A; Lecoules A; Magnani A; Vilette R; Male F; Cagnard N; Delville M; Magrin E; Caccavelli L; Roudaut C; Plantier C; Sobrino S; Gregg J; Nobles CL; Everett JK; Hacein-Bey-Abina S; Galy A; Fischer A; Thrasher AJ; André I; Cavazzana M; Bushman FD
Blood; 2020 Apr; 135(15):1219-1231. PubMed ID: 32040546
[TBL] [Abstract][Full Text] [Related]
36. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Boztug K; Dewey RA; Klein C
Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
[TBL] [Abstract][Full Text] [Related]
37. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.
Mantovani J; Charrier S; Eckenberg R; Saurin W; Danos O; Perea J; Galy A
J Gene Med; 2009 Aug; 11(8):645-54. PubMed ID: 19455589
[TBL] [Abstract][Full Text] [Related]
38. Wiskott-Aldrich syndrome.
Notarangelo LD; Miao CH; Ochs HD
Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
[TBL] [Abstract][Full Text] [Related]
39. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
[TBL] [Abstract][Full Text] [Related]
40. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
